The Effect of Antithrombotic Treatment of Dalteparin after Mitral Valve Repair under Cardiopulmonary Bypass in Dogs

Abstract

We evaluated the effect of ozagrel and darteparin after mitral valve repair under cardiopulmonary bypass in dogs. A total of 32 dogs were included in this study (9.7±2.3 years old, 5.3±3.7 kg). The two out of 32 cases were excluded because of death with aspiration or hypotension within 24 hours after surgery. Dogs (n=14) were treated with hydrochloric acid ozagrel orally (p.o.) for a dose of 5 or 10 mg/kg BID, or Low molecular weight heparin; dalteparin (5 IU/kg/hr) after the operation. The dose of dalteparin was increased gradually (until 50 or 75 IU/kg/hr), and then changed to subcutaneous injection of 50–100 IU/kg/day for 6–12 days (n=16). After that, ozagrel hydrochloride (10 mg/kg p.o., BID), a thoromboxane A 2 synthase inhibitor, was administered for 1 month instead of dalteparin. In this study, it was suggested there were less thrombosis in the darteparin-treated group. The number of platelets increased earlier in darteparin-treated group. Also, there was significant lower rate of hyperlipasemia in the darteparin-treated group. This study has shown the effect of darteparin in preventing adverse events, and it was emphasized the importance of anticoagulation management after mitral valve repair.